PMID- 24297954
OWN - NLM
STAT- MEDLINE
DCOM- 20140502
LR  - 20141107
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 32
IP  - 8
DP  - 2014 Mar 10
TI  - Incidence of new primary melanomas after diagnosis of stage III and IV melanoma.
PG  - 816-23
LID - 10.1200/JCO.2013.49.5572 [doi]
AB  - PURPOSE: New primary melanomas (NPMs) have developed in some patients with 
      metastatic melanoma treated with BRAF inhibitors. We sought to determine the 
      background incidence of spontaneous NPMs after a diagnosis of American Joint 
      Committee on Cancer/International Union Against Cancer stage III or IV melanoma 
      in patients not treated with a BRAF inhibitor. PATIENTS AND METHODS: Patients 
      diagnosed with stage III or IV melanoma at Melanoma Institute Australia between 
      1983 and 2008 were analyzed, and those who received a BRAF inhibitor were 
      excluded. RESULTS: Two hundred twenty-nine (5%) of 4,215 patients with stage III 
      melanoma and 43 (1%) of 3,563 patients with stage IV melanoma had at least one 
      NPM after diagnosis of stage III or IV disease. The 6-month, 1-year, and 10-year 
      cumulative incidence rates of developing an NPM after stage III melanoma were 
      1.2% (95% CI, 0.86% to 1.51%), 1.8% (95% CI, 1.44% to 2.26%), and 5.9% (95% CI, 
      5.08% to 6.74%), respectively. The 3-month, 6-month, and 1-year cumulative 
      incidence rates of NPM after diagnosis of stage IV melanoma were 0.2% (95% CI, 
      0.07% to 0.36%), 0.3% (95% CI, 0.15% to 0.51%), and 0.4% (95% CI, 0.25% to 0.7%), 
      respectively. In both patients with stage III and stage IV melanoma, male 
      patients and patients with a prior history of multiple primaries had a higher 
      incidence of NPM. CONCLUSION: Patients with stage III and stage IV melanoma 
      remain at risk for development of further primary melanomas, particularly if they 
      have a history of multiple primary melanomas before stage III or IV disease. The 
      incidence rates are lower than those reported in patients receiving BRAF 
      inhibitors. However, the results must be compared with caution because 
      dermatologic assessment is more frequent in BRAF inhibitor trials.
FAU - Zimmer, Lisa
AU  - Zimmer L
AD  - Lisa Zimmer and Dirk Schadendorf, University Hospital, University Duisburg-Essen, 
      Essen, Germany; Lauren E. Haydu, Alexander M. Menzies, Richard A. Scolyer, 
      Richard F. Kefford, John F. Thompson, and Georgina V. Long, Melanoma Institute 
      Australia; Alexander M. Menzies, Richard A. Scolyer, Richard F. Kefford, and 
      Georgina V. Long, Sydney Medical School, The University of Sydney; Richard A. 
      Scolyer and John F. Thompson, Royal Prince Alfred Hospital; Lauren E. Haydu and 
      John F. Thompson, The University of Sydney; John F. Thompson, Mater Hospital, 
      Sydney; Richard F. Kefford and Georgina V. Long, Westmead Institute for Cancer 
      Research, Westmead Hospital, Westmead, New South Wales, Australia.
FAU - Haydu, Lauren E
AU  - Haydu LE
FAU - Menzies, Alexander M
AU  - Menzies AM
FAU - Scolyer, Richard A
AU  - Scolyer RA
FAU - Kefford, Richard F
AU  - Kefford RF
FAU - Thompson, John F
AU  - Thompson JF
FAU - Schadendorf, Dirk
AU  - Schadendorf D
FAU - Long, Georgina V
AU  - Long GV
LA  - eng
PT  - Journal Article
DEP - 20131202
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
SB  - IM
CIN - J Clin Oncol. 2014 Oct 1;32(28):3202. PMID: 25185098
CIN - J Clin Oncol. 2014 Oct 1;32(28):3203. PMID: 25185100
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Australia/epidemiology
MH  - Child
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Melanoma/*epidemiology/pathology
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neoplasms, Second Primary/*epidemiology/pathology
MH  - Risk Factors
MH  - Sex Factors
MH  - Skin Neoplasms/*epidemiology/pathology
MH  - Time Factors
MH  - Young Adult
EDAT- 2013/12/04 06:00
MHDA- 2014/05/03 06:00
CRDT- 2013/12/04 06:00
PHST- 2013/12/04 06:00 [entrez]
PHST- 2013/12/04 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
AID - JCO.2013.49.5572 [pii]
AID - 10.1200/JCO.2013.49.5572 [doi]
PST - ppublish
SO  - J Clin Oncol. 2014 Mar 10;32(8):816-23. doi: 10.1200/JCO.2013.49.5572. Epub 2013 
      Dec 2.